Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2443 • ACR Convergence 2025
Mitochondrial dysfunction drives natural killer cell dysfunction in systemic lupus erythematosus
Natalia Fluder¹, Morgane Humbel², Camillo Ribi¹ and Denis Comte¹, ¹Lausanne University Hospital / University of Lausanne, Lausanne, Switzerland, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation and widespread inflammation. Natural killer (NK) cells, essential for immune surveillance,…
Abstract Number: 2425 • ACR Convergence 2025
Neutrophil Transcriptomics in SLE: Exploring Intrinsic, Ex Vivo Adaptation, and CAR-T Cell Therapy-Induced Changes
Ehsan Dehdashtian¹, Stefania Gallucci², Guangnan Hu³, Dominic Borie⁴ and Roberto Caricchio⁵, ¹UMass Chan Medical School, Worcester, MA, ²Temple University School of Medicine, Worcester, MA, ³UMass Chan School of Medicine, Worcester, MA, ⁴Kyverna Therapeutics, Emeryville, CA, ⁵University of Massachusetts Chan Medical School, Worcester, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by dysregulation of the adaptive and innate immune systems. Neutrophils, key players in innate immunity,…
Abstract Number: 2406 • ACR Convergence 2025
Machine Learning-Based Artificial Intelligence in Systemic Lupus Erythematosus: A Systematic Review of Outcome Prediction and Patient Stratification
Jorge Juan Fragío Gil¹, Roxana González Mazario², Pablo Martínez Calabuig³, Laura Salvador Maicas⁴, Mireia Sanmartin Martínez⁴, Iván Jesús Lorente Betanzos⁴, Amalia Rueda Cid⁴, Juan José Lerma Garrido⁴, Isabel Martínez Cordellat⁴ and Cristina Campos Fernández⁵, ¹Hospital General Universitario, Valencia, Spain, ²Hospital General de Valencia, Valencia, Spain, ³Hospital General Universitario de Valencia, Spain/ Uversidad Catolica de Valencia San Vicente Martir, Valencia, Spain, Ontinyent, Spain, ⁴Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ⁵Hospital General de Valencia, Valencia
Background/Purpose: Systematic lupus erythematosus (SLE) is an autoimmune disease with prognostic challenges due to its cyclic diversity. Artificial intelligence and machine learning (ML) has emerged…
Abstract Number: 2389 • ACR Convergence 2025
A Comparison of Patients with Older Onset vs. Younger Onset SLE: A Retrospective Cohort Study
Chelsea Guan¹, Milad Heydari-Kamjani², Keri Ann Pfeil¹, Elleson Harper¹, Lindsay Frumker³, Meghan Gump¹ and Omer Pamuk², ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ³University hospitals Cleveland medical center, Highland Heights, OH
Background/Purpose: SLE is a systemic autoimmune disease that can present at different ages and with various multiorgan complications. In this study, we aimed to analyze…
Abstract Number: 2225 • ACR Convergence 2025
The Impact of Pregnancy Planning on the Prevalence of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Retrospective Study from Three Japanese Tertiary Referral Centers
Takehiro Nakai¹, Nanase Honda², YORIKAZU HASHIMOTO³, Eri Soga⁴, Sho Fukui⁵, Ayako Kitada⁶, Kensuke Nakanishi⁷, Naoto Yokogawa⁸ and Masato Okada⁹, ¹Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ²Tokyo Metropolitan Matsuzawa hospital, Setagaya-ku, Tokyo, Japan, ³Nanbu Medical Center & Children's Medical Center, Naha, Japan, ⁴Tokyo Metropolitan Tama Medical Center, Tama, Tokyo, Japan, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ⁶St Luke's International hospital, nagareyama-shi, chiba- ken, Japan, ⁷Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Haebaru, Okinawa, Japan, ⁸Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Tokyo, Japan, ⁹St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with a higher risk of adverse pregnancy outcomes (APOs) compared to the general population. Although several APO risk…
Abstract Number: 2150 • ACR Convergence 2025
Rheum to Grow:An Approach Towards Human Centered Design through a Qualitative Analysis on the Transition from Pediatric to Adult Rheumatology
Lillian Chang¹, Rhea Sharma², Elyse Guziewicz¹, Jordan Jackson³, Katrina Romagnoli¹, Gemme Campbell¹, Saritha Korukonda¹, Priyanka Pawar¹, Jonida Cote⁴, Thomas Davis¹ and Emily Brunner¹, ¹Geisinger, Danville, PA, ²Geisinger Medical Center Internal Medicine Residency, Danville, PA, ³Geisinger Medical Center Medicine-Pediatrics Residency, Danville, PA, ⁴Geisinger Health System, Wilkes-Barre, PA
Background/Purpose: Up to half of patients who transition to adult care are lost to follow up within 2 years of transfer from pediatric to adult…
Abstract Number: 1897 • ACR Convergence 2025
Changes in SLE Mortality During and After the COVID-19 Pandemic
Laura Hernandez¹ and Ram Singh², ¹University of California, Los Angeles, Murrieta, CA, ²UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are vulnerable to infections due to both underlying immune dysfunction and the use of immunosuppressive therapies. Hence, it…
Abstract Number: 1842 • ACR Convergence 2025
Social Vulnerability Index, Type 2 Lupus Symptoms, and Select Dysregulated Immune Features Identify Stage 2 (Pre-classification) SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
Melissa Munroe¹, Zoe Reed², Joel Guthridge², Diane Kamen³, Timothy Niewold⁴, Kendra Young⁵, Angel Weng⁵, Emma Wu⁵, Gary Gilkeson⁶, Michael Weisman⁷, Mariko Ishimori⁷, Daniel Wallace⁸, John Harley⁹, David Karp¹⁰, Jill Norris¹¹ and Judith James², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Medical University of South Carolina, Johns Island, SC, ⁴Hospital for Special Surgery, New York, New York, ⁵Colorado School of Public Health, Aurora, CO, ⁶Medical University of South Carolina, Charleston, SC, ⁷Cedars-Sinai Medical Center, LOS ANGELES, CA, ⁸Cedars Sinai Medical Center, Studio City, CA, ⁹US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹⁰UT Southwestern Medical Center, Dallas, TX, ¹¹Colorado School of Public Health, Denver, CO
Background/Purpose: Socioeconomic environmental factors are associated with SLE disease activity and early mortality and may contribute to disease progression in at-risk populations. Blood relatives (BRs)…
Abstract Number: 1763 • ACR Convergence 2025
Spatial Organization and Function of Disease-Associated Macrophages in Lupus Nephritis: Insights from Cross-Species Analyses
Paul Hoover¹, Chirag Raparia², Rollin Leavitt³, Nir Hacohen⁴, Arnon Arazi⁵ and Anne Davidson², ¹Brigham and Women's Hospital, Boston, MA, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Broad Institute, Boston, MA, ⁴Broad Institute, Cambridge, MA, ⁵The Feinstein Institutes for Medical Research, Manhasset
Background/Purpose: Myeloid cells are linked to kidney injury in lupus nephritis (LN) but lack targeted therapies, underscoring the need to better understand myeloid biology in…
Abstract Number: 1699 • ACR Convergence 2025
Protein-coding Somatic Genetic Variation in Lymphocytes in Systemic Lupus Erythematosus
Siva Kasinathan¹, Minh Pham² and Ansuman Satpathy², ¹Stanford University School of Medicine, Palo Alto, CA, ²Stanford University School of Medicine, Stanford, CA
Background/Purpose: The genetic and environmental factors underlying pathogenesis of systemic lupus erythematosus (SLE) are incompletely resolved. While inherited genetic variation has been extensively queried in…
Abstract Number: 1552 • ACR Convergence 2025
Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
Zahi Touma¹, Ian Bruce², Richard Furie³, Eric Morand⁴, Raj Tummala⁵, Shelly Chandran⁶, Gabriel Abreu⁷, Jacob Knagenhjelm⁷, Cathy Emmas⁸, Lyra Agustin⁸, Alessandra Venerus⁹, Tarana Mehdikhanova¹⁰, Zheyuan Yang¹⁰ and Miina Waratani⁸, ¹University of Toronto, Toronto, ON, Canada, ²Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁵AstraZeneca, BioPharmaceuticals R&D, Gaithersburg, Gaithersburg, MD, ⁶AstraZeneca, Medical & Scientific Affairs, R&I, Mississauga, ON, Canada, ⁷AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden, ⁸AstraZeneca, BioPharmaceuticals Medical, Cambridge, United Kingdom, ⁹IQVIA, EMEA Real World Methods and Evidence Generation, Milan, Italy, ¹⁰IQVIA, EMEA Real World Methods and Evidence Generation, London, United Kingdom
Background/Purpose: Patients with systemic lupus erythematosus (SLE) can develop cardiovascular (CV) damage (angina, myocardial infarction, ventricular dysfunction, valvular disease, or pericarditis for 6 months/pericardiectomy) particularly…
Abstract Number: 1534 • ACR Convergence 2025
Rapid Oral Glucocorticoid Discontinuation or Dose Reduction Among US Patients with SLE Receiving Belimumab in a Real-World Setting
Yan Chen¹, Maral DerSarkissian¹, Shumin Rui¹, Justin Clark¹, Daniel Moldaver², Jeffrey J. Ellis³, Karen Worley³ and Aarat M Patel⁴, ¹Analysis Group, Los Angeles, CA, ²GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ⁴GSK, US Medical Affairs, Durham, NC
Background/Purpose: Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells that drive lupus disease activity, is approved…
Abstract Number: 1515 • ACR Convergence 2025
Machine Learning–Defined Subtypes of Systemic Lupus Erythematosus Identify Distinct Immunologic and Molecular Signatures
Yuke Hou¹, Bo Wei², Jingyuan Liang³, Yujia Zhai⁴, Yan Wang⁵, Haihong Yao¹ and Zhanguo Li⁶, ¹Peking University People’s Hospital, Beijing, Beijing, China (People's Republic), ²Zhongshan Hospital Xiamen University, Xiamen, Fujian, China (People's Republic), ³North China University Of Science And Technology Affiliated Hospital, Tianjin, Tianjin, China (People's Republic), ⁴Bayannur City Hospital, Bayannur, Nei Mongol, China (People's Republic), ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, China (People's Republic), ⁶Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, Beijing, Beijing, China (People's Republic)
Background/Purpose: To refine clinical subtypes of systemic lupus erythematosus (SLE) using unsupervised machine learning, and to elucidate the molecular basis of disease heterogeneity through integrated…
Abstract Number: 1492 • ACR Convergence 2025
Prevalence and Risk Factors of Gynecologic Cancers in Female Patients with Systemic Lupus Erythematosus
Katherine Moseley¹, Dulaney Wilson², Emily Vara¹ and Diane Kamen³, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Medical University of South Carolina, Johns Island, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic systemic autoimmune disorder that is nine times more prevalent in women. Patients with SLE are at an…
Abstract Number: 1474 • ACR Convergence 2025
Rethinking Heart Risk Prediction for Lupus Patients
Aretha On¹, Xiwei Yang¹, Shae Chambers², Hammad Ali³, Touraj Khosravi-Hafshejani³, Lais Lopes Almeida Gomes², Rui Feng⁴, Kevin Jon Williams⁵ and Victoria Werth⁶, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, U.S./Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, U.S., Philadelphia, PA, ⁴Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA, ⁵Department of Cardiovascular Sciences, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA, Philadelphia, PA, ⁶University of Pennsylvania, Wynnewood, PA
Background/Purpose: Patients with lupus erythematosus (LE) are at an increased risk of clinical events from atherosclerotic cardiovascular disease (ASCVD), yet the accuracy of risk estimation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].